Gofen & Glossberg LLC IL decreased its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 1.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 299,718 shares of the biopharmaceutical company’s stock after selling 5,780 shares during the period. Gilead Sciences makes up about 1.0% of Gofen & Glossberg LLC IL’s holdings, making the stock its 28th largest position. Gofen & Glossberg LLC IL’s holdings in Gilead Sciences were worth $23,714,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in shares of Gilead Sciences by 4.0% in the second quarter. Bank of New York Mellon Corp now owns 26,617,229 shares of the biopharmaceutical company’s stock worth $2,220,410,000 after buying an additional 1,023,299 shares during the last quarter. BlackRock Fund Advisors raised its position in shares of Gilead Sciences by 2.6% in the second quarter. BlackRock Fund Advisors now owns 24,369,287 shares of the biopharmaceutical company’s stock worth $2,032,886,000 after buying an additional 612,544 shares during the last quarter. Capital World Investors raised its position in shares of Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock worth $1,277,907,000 after buying an additional 3,380,000 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Gilead Sciences by 17.0% in the second quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company’s stock worth $1,113,383,000 after buying an additional 1,942,138 shares during the last quarter. Finally, Parnassus Investments CA raised its position in shares of Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock worth $705,774,000 after buying an additional 2,640,284 shares during the last quarter. 73.59% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.74% on Tuesday, hitting $75.09. The stock had a trading volume of 1,570,440 shares. Gilead Sciences Inc. has a one year low of $71.39 and a one year high of $107.38. The stock has a market cap of $98.93 billion, a PE ratio of 6.94 and a beta of 1.25. The company’s 50 day moving average is $74.54 and its 200 day moving average is $80.07.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $2.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The business had revenue of $7.40 billion for the quarter, compared to analysts’ expectations of $7.47 billion. During the same period last year, the business earned $3.22 earnings per share. The company’s revenue for the quarter was down 9.6% on a year-over-year basis. Equities research analysts predict that Gilead Sciences Inc. will post $11.47 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 29th. Stockholders of record on Thursday, December 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio (DPR) is 17.44%.

TRADEMARK VIOLATION WARNING: “Gofen & Glossberg LLC IL Reduces Position in Gilead Sciences Inc. (GILD)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/29/gofen-glossberg-llc-il-reduces-position-in-gilead-sciences-inc-gild.html.

Several equities research analysts have recently issued reports on GILD shares. Jefferies Group raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $76.89 to $91.00 in a research note on Tuesday, September 6th. Piper Jaffray Cos. set a $108.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Sunday, August 21st. RBC Capital Markets set a $105.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, August 11th. Berenberg Bank started coverage on Gilead Sciences in a research note on Monday, September 12th. They issued a “buy” rating and a $112.00 price objective for the company. Finally, Leerink Swann set a $112.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, September 22nd. Ten analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $97.90.

In other news, insider John C. Martin sold 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $77.48, for a total transaction of $7,748,000.00. Following the completion of the transaction, the insider now directly owns 3,287,810 shares of the company’s stock, valued at approximately $254,739,518.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the transaction, the director now directly owns 121,761 shares of the company’s stock, valued at $9,115,028.46. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.